Abstract
Adriamycin (ADM) was chemically conjugated to a murine monoclonal antibody, A0011, which recognizes the c-erbB-2 product, via a disulfide bond using N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP) and 2-iminothiolane (2-IT). The molar ratio of ADM to the monoclonal antibody ranged from 15:1 to 25:1 and enzyme-linked immunosorbent assay (ELISA) showed that the binding activity of the conjugate was almost retained. We compared the efficacy of A0011 alone, ADM alone, the A0011-ADM conjugate, and a nonspecific murine IgM-ADM conjugate, against the human breast cancer cell lines SK-BR-3, MDA-MB-361, MCF-7, and BT-20. The A0011-ADM conjugate was observed to be ten times more cytotoxic to the cell lines overexpressing the c-erbB-2 product, namely, SK-BR-3 and MDA-MB-361, than free ADM, but it showed weak cytotoxicity against the cell lines with a low level of c-erbB-2 product expression, namely, MCF-7 and BT-20. However, free A0011 and nonspecific murine IgM-ADM conjugate showed no cytotoxicity toward any of the four cell lines, while the addition of a tenfold molar excess of A0011 inhibited conjugate cytotoxicity. These data suggest that conjugate cytotoxicity is antibody-mediated. Moreover, conjugate cytotoxicity at 10−6M was correlated with antigen volume, and the data were fitted to the regression equation y=−11.63logX+116.38 where the correlation coefficient =0.950. Our results indicate that targeting therapy aiming at the c-erbB-2 product may be useful in the treatment of breast cancers overexpressing the c-erbB-2 product.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T (1986) The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644–1646
Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seebug PH, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132–1139
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–181
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SC, Keith DE, Levin WJ, Stuart SC, Udove J, Ullrich A, Press MF (1989) Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244:707–712
Fukushige S, Matsubara K, Yoshida M, Sakai M, Suzuki T, Semba K, Toyoshima K, Yamamoto T (1986) Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 6:955–958
Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L, Robinson RA (1990) p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50:5184–5191
Fiore PPD, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA (1987) erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178–182
Hudziak RM, Schlessinger J, Ullrich A (1987) Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84:7159–7163
McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BMJ, Carney DN (1991) Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51:3296–3303
Ozawa S, Ueda M, Ando N, Abe O, Minoshima S, Shimizu N (1989) Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor. Int J Cancer 43:152–157
Hirota N, Ueda M, Ozawa S, Abe O, Shimizu N (1989) Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody. Cancer Res 49:7106–7109
Osaku M, Ueda M, Ando N, Shinozawa Y, Hirota N, Shimizu N, Abe O (1991) Targeted killing of squamous carcinoma cells by a monoclonal antibody-pepleomycin conjugate which recognizes the EGF receptor. Anticancer Res 11:1951–1956
Carter SK (1975) Adriamycin — A Review. J Natl Cancer Inst 55:1265–1274
Young RC, Ozols RF, Myers CE (1981) The anthracycline antineoplastic drugs. N Engl J Med 305:139–153
Braslawsky GR, Edson MA, Pearce W, Kaneko T, Greenfield RS (1990) Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing. Cancer Res 50:6608–6614
Dillman RO, Shawler DL, Johnson DE, Meyer DL, Koziol JA, Frincke JM (1986) Preclinical trials with combinations and conjugates of T101 monoclonal antibody and doxorubicin. Cancer Res 46:4886–4891
Galun E, Shouval D, Adler R, Shahaar M, Wilchek M, Hurwitz E, Sela M (1990) The effect of anti-α-fetoprotein-adriamycin conjugate on a human hepatoma. Hepatology 11:578–584
Hurwitz E, Levy R, Maron R, Wilchek M, Arnon R, Sela M (1975) The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res 35:1175–1181
Pimm MV, Jones JA, Price MR, Middle JG, Embleton MJ, Baldwin RW (1982) Tumour localization of monoclonal antibody against a rat mammary carcinoma and suppression of tumour growth with Adriamycin-antibody conjugates. Cancer Immunol Immunother 12:125–134
Yeh MY, Roffler SR, Yu MH (1992) Doxorubicin: monoclonal antibody conjugate for therapy of human cervical carcinoma. Int J Cancer 51:274–282
Yang HM, Reisfeld RA (1988) Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc Natl Acad Sci USA 85:1189–1193
Greenfield RS, Kaneko T, Daues A, Edson MA, Fitzgelald KA, Olech LJ, Grattan JA, Spitalny GL, Braslawsky GA (1990) Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. Cancer Res 50:6600–6607
Mori S, Akiyama T, Yamada Y, Morishita Y, Sugawara I, Toyoshima K, Yamamoto T (1989) C-erbB-2 gene product, a membrane protein commonly expressed on human fetal epithelial cells. Lab Invest 61:93–97
Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD, Shepard HM, Kuang WJ, Wood WI, Goeddel DV, Vandlen RL (1992) Identification of heregulin, a specific activator or p185erbB2. Science 256:1205–1210
Lupu R, Colomer R, Kannan B, Lippman ME (1992) Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. Proc Natl Acad Sci USA 89:2287–2291
Mori S, Mori Y, Mukaiyama T, Yamada Y, Sonobe Y, Matsushita H, Sakamoto G, Akiyama T, Ogawa M, Shiraishi M, Toyoshima K, Yamamoto T (1990) In vitro and in vivo release of soluble c-erbB-2 potein from human carcinoma cells. Jpn J Cancer Res 81:489–494
Colombatti M, Nabholz M, Gros O, Bron C (1983) Selective killing of target cells by antibody-ricin A chain or antibody-gelonin hybrid molecules: comparison of cytotoxic potency and use in immunoselection procedures. J Immunol 131:3091–3095
Lambert JM, Senter PD, Yau-Young A, Blatter WA, Goldmacher VS (1985) Purified immunotoxins that are reactive with human lymphoid cells. J Biol Chem 260:12035–12041
Fitzgerald DJ, Willingham MC, Pastan I (1986) Antitumor effect of an immunotoxin made with Pseudomonas exotoxin in a nude mouse model of human ovarian cancer. Proc Natl Acad Sci USA 83:6627–6630
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jinno, H., Ueda, M., Enomoto, K. et al. Effectiveness of an adriamycin immunoconjugate that recognizes the c-erbB-2 product on breast cancer cell lines. Surg Today 26, 501–507 (1996). https://doi.org/10.1007/BF00311556
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00311556